

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**VOLUNTARY ANNOUNCEMENT
PROPOSED ON-MARKET SHARE REPURCHASE**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated June 10, 2022 in relation to, among others, the general mandate to repurchase (the “**Repurchase Mandate**”) shares of the Company (the “**Shares**”) granted by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting of the Company held on June 10, 2022 (the “**AGM**”).

Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 425,926,547 Shares, being 10% of the total number of issued Shares as at the date of the AGM, on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The board of directors (the “**Board**”) of the Company hereby announces that, on September 23, 2022, it has resolved to utilize the Repurchase Mandate to repurchase Shares in the open market from time to time at an aggregate price up to US\$300 million (the “**Proposed Share Repurchase**”).

The Board considers that the current trading price of the Shares does not reflect their intrinsic value or the actual business prospects of the Group, and it presents a good opportunity for the Company to further repurchase the Shares. Further, the financial position of the Company remains solid and healthy. The Board believes the Proposed Share Repurchase and subsequent cancellation of the repurchased Shares will not only enhance the value of the Shares, thereby improving the return to the Shareholders, but also reduce the impact of the potential dilutive effects on the Company’s shareholdings from the Group’s various equity incentive schemes. In addition, the Proposed Share Repurchase reflects the Company’s recognition of its own value and the confidence in its strong growth prospects. In light of the above, the Board believes that the Proposed Share Repurchase is in the best interests of the Company and its Shareholders as a whole.

The Company will conduct the Proposed Share Repurchase in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and other applicable laws and regulations.

Shareholders and potential investors of the Company should note that any further exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share repurchases or whether or not the Company will make any repurchase at all. Therefore, Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, September 26, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*